Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Miller, D.; Filiaci, V.; Mannel, R.; Cohn, D.; Matsumoto, Takashi; Tewari, K.; DiSilvestro, P.; Pearl, M.; Argenta, P.; Powell, M.; Zweizig, S.; Warshal, D.; Hanjani, P.; Carney, M.; Q. Huang, Helen; Cella, D.; Zaino, R.; Fleming, G.

doi:10.1200/JCO.20.01076

Public

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

Shared by NobleBlocks on Sep 29, 2020 • 12:00 AM UTC

Authors:

D. Miller

V. Filiaci

R. Mannel

Abstract

PURPOSE Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS GOG0209 was a phase II...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!